Immunocytokine sequences and uses thereof

• US 20070059282A1
• Filed: 11/15/2006
• Published: 03/15/2007
• Est. Priority Date: 12/17/2002
• Status: Active Grant

• Current Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Original Assignee: EMD Lexigen Research Center Corp.
• Inventors: Lo, Kin-Ming, Gillies, Stephen, Qian, Susan
• Granted Patent: US 7,767,405 B2
• Time in Patent Office: Days
• US Class Current: 424/85.100
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 16/467 Igs with modifications in the FR-residues only
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.

Claims

1-13. -13. (canceled)

14. A method for targeting a cell with GD2 on its surface, the method comprising administering an antibody variable region comprising amino acids 1-23 of SEQ ID NO:

1.

15. The method of claim 14, wherein the cell is a tumor cell.

27. The method of claim 14, wherein the antibody variable region further comprises amino acids 24-113 of SEQ ID NO:

1.

16-26. -26. (canceled)

28. A method for targeting a cell with GD2 on its surface, the method comprising administering an antibody variable region comprising amino acids 1-25 of SEQ ID NO:

2.

29. The method of claim 28, wherein the antibody variable region further comprises amino acids 26-113 of SEQ ID NO:

2.

30. The method of claim 29, where in the antibody variable region further comprises the amino acid sequence set forth in SEQ ID NO:

1.

31. A method for targeting a cell with GD2 on its surface, the method comprising administering an antibody variable region comprising amino acids 67-98 of SEQ ID NO:

2.

32. The method of claim 31, wherein the antibody variable region further comprises amino acids 1-66 and 99-113 of SEQ ID NO:

2.